结直肠癌患者FOLFOX化疗与GSTP1,XRCC1基因多态性的研究

目的 探究结直肠癌患者FOLFOX化疗与GSTP1,XRCC1基因多态性的关系。方法 选取湖南省肿瘤医院2014年1月～12月收治的结直肠癌术后患者60例作为研究对象,给予改良FOLFOX方案化疗,并测定患者GSTP1,XRCC1基因序列多态性,统计患者疗效并探究疗效与GSTP1,XRCC1基因序列多态性的关系。结果 患者完全缓解与部分缓解的例数和患者稳定与进展的例数与患者的性别、年龄、肿瘤位置、病理分化、TNM分期无关(χ2=0.136～1.837,P值均>0.05); 携带GSTP1 A/A基因型患者41例(68.3%),携带A/G基因型患者14例(23.3%),携带 G/G基因型患者5例(8.3%),GSTP1基因野生型(A/A)患者治疗有效率低于GSTP1基因突变型(A/G+G/G)患者(χ2=4.493,P=0.034)。携带XRCC1 G/G基因型患者35例(58.3%),携带G/A基因型患者22例(36.7%),携带A/A基因型患者3例(5%),XRCC1基因野生型(G/G)患者治疗有效率高于突变型(G/A+A/A)患者(χ2=4.691,P=0.030)。结论 研究表明结直肠癌患者GSTP1(A/A),XRCC1(G/G)基因多态性与FOLFOX化疗的敏感性相关。

Relationship between FOLFOX Chemotherapy of Colorectal Cancer Patients and GSTP1,XRCC1 Gene Polymorphism

Objective To explore the relationship between FOLFOX Chemotherapy and GSTP1,XRCC1 gene polymorphism in patients with colorectal cancer.Methods 60 cases of colorectal cancer treated in Tumor hospital of Hunan Province from January to December 2014 were selected as the research object.Treat patients with modified FOLFOX regimen,determined the GSTP1,XRCC1 gene sequence polymorphism,and explored the relationship between the efficacy and the GSTP1,XRCC1 gene sequence polymorphism.Results The number of patients with complete remission and partial remission and the number of patients with stable and progress were not related to thegender,age,tumor location,pathological differentiation,TNM staging of patients(χ2=0.222～1.8,P>0.05).Of all cases,the frequencies of GSTP1A/A,A/G and G/G genotype were 68.3%,23.3% and 8.3%,respectively.GSTP1 gene wild-type(A/A)patients were treated with less efficiency than the GSTP1 gene mutation type(A/G+G/G)patients(χ2=4.493,P=0.034).Of all cases,thefrequencies of XRCC1 G/G,G/A and A/A genotype were 58.3%,36.7% and 5%,respectively.XRCC1 gene wild type(G/G)patients with effective rate was higher thanthat of mutant type(G/A+A/A)patients(χ2=4.691,P=0.030).Conclusion The study showed that GSTP1(A/A),XRCC1(G/G)gene polymorphism may be associated with clinical response to FOLFOX chemotherapy in advanced colorectal cancer.